Site-directed chemotherapy with a drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM.

Abstract

Xenogeneic antibodies against the cell-surface IgM of a B-cell lymphoma (38C-13) were coupled through a dextran bridge to the anti-neoplastic drug, daunomycin. The conjugate maintained both its antibody and its drug activity. The effectiveness of the conjugate was tested in vivo in mice challenged with the 38C-13 lymphoma. Drug conjugates of the idiotypic antibodies injected intraperitoneally 2 days after tumor transplantation almost completely inhibited tumor development. The controls, daunomycin-dextran-goat anti-DNP, free daunomycin, or the antibodies alone had no effect or only delayed the tumor development.

• Authors: E Hurwitz, R Kashi, D Burowsky, R Arnon, J Haimovich
• Journal: International journal of cancer (Int J Cancer) Vol. 31 Issue 6 Pg. 745-8 (Jun 15 1983) ISSN: 0020-7136 [Print] United States
• PMID: 6862683 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunoglobulin Fab Fragments
• Immunoglobulin Idiotypes
• Immunoglobulin M
• Receptors, Antigen, B-Cell
• Daunorubicin

Topics

• Animals
• Antibody Specificity
• Daunorubicin (administration & dosage)
• Drug Evaluation, Preclinical
• Immunization, Passive
• Immunoglobulin Fab Fragments (administration & dosage)
• Immunoglobulin Idiotypes (administration & dosage)
• Immunoglobulin M (immunology)
• Lymphoma (drug therapy, immunology)
• Mice
• Neoplasms, Experimental (drug therapy, immunology)
• Receptors, Antigen, B-Cell (immunology)